foroxymithine

isolated from Streptomyces nitrosporeus; structure given in first source; MW 575.57; MF C22-H37-N7-O11

Also Known As:

L-Serinamide, N2-acetyl-N5-formyl-N5-hydroxy-L-ornithyl-N-(3-(5-(3-(formylhydroxyamino)propyl)-3,6-dioxo-2-piperazinyl)propyl)-N-hydroxy-, (2S-cis)-

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 01/01/1990 - "Foroxymithine alone had no anti-tumor activity. "
2.	Leukemia 04/01/1987 - "Administration of both erbstatin and foroxymithine showed antineoplastic activity against L-1210 leukemia."
3.	Breast Neoplasms (Breast Cancer) 01/01/1990 - "The growth of MCF-7, a human mammary carcinoma, in athymic nude mice was inhibited by intraperitoneal administration of erbstatin for 14 days in combination with an iron chelator, foroxymithine, which inhibits the decomposition of erbstatin. "
4.	Bone Resorption 06/01/1993 - "Some protease inhibitors, e.g., E-64, pepstatin A, phosphoramidon, amastatin, bestatin, foroxymithine, did not influence the bone resorption, but some serine protease inhibitors such as PMSF, TLCK, TPCK and elastatinal inhibited the bone resorption at 10(-5) M, 10(-4) M, 10(-4) M, 10(-4) M, respectively. "

1.	erbstatin
2.	Serine Proteinase Inhibitors (Serine Protease Inhibitors)
3.	Tosylphenylalanyl Chloromethyl Ketone (TPCK)
4.	Tosyllysine Chloromethyl Ketone
5.	Protease Inhibitors (Protease Inhibitor)
6.	Iron
7.	Dihydrotachysterol (AT 10)
8.	Chelating Agents
9.	Antineoplastic Agents (Antineoplastics)
10.	pepstatin (pepstatin A)